++
For further information, see CMDT Part 6-43: Pruritus (Itching)
++
Causes of generalized pruritus
Dry skin
Scabies
Atopic dermatitis
Insect bites, pediculosis
Contact dermatitis, fiberglass dermatitis
Drug reactions
Urticaria
Psoriasis
Lichen planus, lichen simplex chronicus
Persistent pruritus not explained by cutaneous disease or associated with a primary skin eruption should prompt a staged workup for systemic causes
Other causes
Endocrine disorders, such as hypothyroidism, hyperthyroidism, or hyperparathyroidism
Psychiatric disturbances
Lymphoma
Leukemia
Iron deficiency anemia
Certain neurologic disorders
Pruritus accompanying a specific skin disease will subside when the skin disease is controlled
Pruritus accompanying serious internal disease may not respond to any type of therapy
++
Severity of the liver disease may not correlate with the degree of itching
Burning or itching involving the face, scalp, and genitalia may be manifestations of primary depression and is treatable with antidepressant drugs
++
Clinical
Role of interleukins
Increased interleukin-31 (IL-31) signaling through the IL-31 receptor on epithelial cells and keratinocytes is associated with itch, especially in allergic skin disease
IL-4 and IL-13 (via binding to the IL-4R) likely lower the itch threshold of sensory neurons
Janus kinase signaling (which occurs downstream from the IL-4R) also seems important in the pathophysiology of itch
++
Emollients for dry skin (see Table 6–2)
In neuropathic disease, especially in diabetic patients, neurally acting agents may be beneficial
In refractory cases, the following can be tried:
In cancer-associated and other forms of pruritus, aprepitant (Emend) 80 mg orally daily for several days can be dramatically effective
Phototherapy with ultraviolet B or PUVA may help the pruritus of uremia in conjunction with hemodialysis and to a lesser degree the pruritus of liver disease
In pruritus associated with liver disease, naltrexone and nalmefene have been shown to provide relief
In advanced chronic kidney disease, gabapentin or mirtazapine may be effective
Crisaborole (a topical phosphodiesterase 4 inhibitor) and dupilumab (an interleukin 4 inhibitor)
IL-31 blockade (nemolizumab), IL-4 blockade (dupilumab), and inhibition of the Janus kinase pathway (tofacitinib) appear efficacious in the treatment of chronic pruritus